Vor Biopharma Inc. Quarterly Debt-to-equity in % from Q3 2021 to Q3 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Vor Biopharma Inc. quarterly Debt-to-equity history and growth rate from Q3 2021 to Q3 2024.
Vor Biopharma Inc. Debt-to-equity for the quarter ending September 30, 2024 was 40 %, a 80.3% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q3 2024	40	+17.8	+80.3%	Sep 30, 2024
Q2 2024	33.5	+11	+48.6%	Jun 30, 2024
Q1 2024	28.5	+4.77	+20.1%	Mar 31, 2024
Q4 2023	24.9	+1.06	+4.44%	Dec 31, 2023
Q3 2023	22.2	+0.24	+1.09%	Sep 30, 2023
Q2 2023	22.5	+5.26	+30.4%	Jun 30, 2023
Q1 2023	23.7	+10.7	+81.5%	Mar 31, 2023
Q4 2022	23.9	+13.2	+124%	Dec 31, 2022
Q3 2022	22	+6.89	+45.7%	Sep 30, 2022
Q2 2022	17.3			Jun 30, 2022
Q1 2022	13.1			Mar 31, 2022
Q4 2021	10.6			Dec 31, 2021
Q3 2021	15.1			Sep 30, 2021

* An asterisk sign (*) next to the value indicates that the value is likely invalid.